Product Data Sheet
Ibandronate Sodium Monohydrate 138926-19-9 HY-B0515 359.23 C9H24NNaO8P2 >98%
Product Name: CAS No.: Cat. No.: MWt: Formula: Purity :
DMSO <1 mg/mL; Water 72 mg/mL
Mechanisms: Pathways:Others; Target:Others Biological Activity: Ibandronate is a highly potent nitrogen nitrogen-containing containing bisphosphonate used for the treatment of osteoporosis. Target: Others Ibandronate (1.25-2 μM) significantly reduces endothelial cell growth, while ibandronate (2 μM) also significantly reduces capillary-like tube formation and increases apoptosis of endothelial cells. Ibandronate (< 100 μM) dose-dependently increases VEGF expression in endothelial cells . Ibandronate (< 100 μM) inhibits growth of both prostate cancer cell lines (LNCaP and PC-3) in a dose dependent manner . Ibandronate administered either daily y( (2.5 mg) g) or intermittently y( (20 mg g every y other day y for 12 doses every 3 months) significantly reduces the risk of new morphometric vertebral fractures by 62% and 50% (p = 0.0006), respectively, in osteoporotic women after 3 years' treatment. Ibandronate administered either daily (2.5 mg) or intermittently (... References: . Morgan, C., S. Jeremiah, and J. Wagstaff, Metronomic administration of ibandronate and its antiangiogenic effects in vitro. Microvasc Res, 2009. 78(3): p. 453-8. . [ ] Epplen, pp R., et al., Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines. Acta Oncol, 2011. 50(1): p. 127-33. . Chesnut, I.C., et al., Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res, 2004. 19(8): p. 1241-9. . Bauss, F., et al., Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol, 2002. 29(10): p. 2200-8. ...
Caution: Not fully tested. For research purposes only Medchemexpress LLC
m o c . s s e r p x e m e h c d e m . w w w : b e AW Sm Uo ,c 0 4. 5s 8s 0e r p Jx Ne ,m n e oh t c e cd ne i rm P @ ,o y f an Wi : l ni oa sm n iE k l i W 8 1